Clinical Trials Logo

Endometrial Stromal Tumors clinical trials

View clinical trials related to Endometrial Stromal Tumors.

Filter by:
  • None
  • Page 1

NCT ID: NCT05310318 Recruiting - Recurrence Clinical Trials

Prognosis of Low-grade Endometrial Stromal Sarcoma

Start date: March 26, 2022
Phase:
Study type: Observational

This study is to investigate the survival outcomes and fertility outcomes in patients with uterine low-grade endometrial stromal sarcoma (LGESS) treated in Peking Union Medical College Hospital. All primary and recurrent LGESS patients will be enrolled. The study will collect retrospectively data consisting of epidemiological characteristics, surgical, medical treatment and adjuvant therapy. Details about recurrence, mortality, pregnancy and obstetrical outcomes are also followed as primary endpoints. Fertility-sparing procedures, including uterine-sparing and ovary-sparing surgeries will be recorded specifically.

NCT ID: NCT03624244 Recruiting - Clinical trials for Low Grade Endometrial Stromal Sarcoma

Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)

BFR-ESS
Start date: January 23, 2019
Phase: Phase 2
Study type: Interventional

The primary objective is to compare the progression-free survival (PFS) between aromatase inhibitors interruption and aromatase inhibitors maintenance strategies in patients with a locally advanced or metastatic Low Grade Endometrial Stromal Sarcoma (LGESS).

NCT ID: NCT03509207 Terminated - Leiomyosarcoma Clinical Trials

Vorinostat (SAHA) in Uterine Sarcoma

Start date: December 14, 2017
Phase: Phase 2
Study type: Interventional

Uterine sarcomas are rare tumors with a poor prognosis. The main purpose of this phase II proof-of-principle- pilot study is to test the efficacy of the hydroxamic acid-based Histone deacetylase inhibitor (HDACI) Vorinostat (SAHA) as monotherapy in patients with HDAC-positive, progressive, metastatic uterine sarcomas and mixed epithelial and mesenchymal tumors after prior anti-proliferative therapy.

NCT ID: NCT02829437 Recruiting - Clinical trials for Endometrial Stromal Tumors

Observational Study on Endometrial Stromal Tumors

EST
Start date: October 2016
Phase:
Study type: Observational

Observational, retrospective and prospective study on Endometrial Stromal Tumor (EST)

NCT ID: NCT00505739 Completed - Endometrial Cancer Clinical Trials

Mifepristone for Patients With Endometrial Cancer and LGESS

Start date: September 2001
Phase: Phase 2
Study type: Interventional

Primary Objectives: 1. To determine the antitumor activity of Mifepristone (RU-486) in patients with advanced or recurrent endometrioid adenocarcinoma or low grade endometrial stromal sarcoma (LGESS). 2. To evaluate the quantitative and qualitative toxicities of Mifepristone in this patient population. 3. To evaluate at a tissue level the effect of Mifepristone on estrogen and progesterone receptors post treatment and to evaluate other markers that may reflect effects of Mifepristone on cancer cell growth. 4. To evaluate the effect of the agent and dosing schedule on the patient's quality of life.